Collaborative Research: Pacific Research Center for Marine Biomedicine

合作研究：太平洋海洋生物医学研究中心

• 批准号: 0911000
• 负责人: Edward Laws
• 金额: $ 136.79万
• 依托单位: University of Hawaii
• 依托单位国家: 美国
• 项目类别: Continuing Grant
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-06-01 至 2012-05-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0911000&HistoricalAwards=false
• 关键词: Collaborative; Research; Pacific; Center; Marine

This accomplishment-based renewal of the Pacific Research Center for Marine Biomedicine (PRCMB) will be a collaboration between the University of Hawaii, Stanford, and Jackson State University. Research activities will be focused on two areas: (1) pathogens in tropical marine waters and (2) marine toxins and pharmaceutical lead discovery. This new research follows logically from accomplishments and discoveries made during the first phase of PRCMB funding. The pathogen and pathogen indicator work will focus on two streams that discharge to the ocean, one tropical (Kaelepulu on the island of Oahu) and the other temperate (San Pedro Creek in California). Monthly sampling at the two streams will be used to characterize seasonal variability in pathogen indicators and pathogen (bacterial and viral) concentrations using both culture-dependent and culture-independent (PCR-based) methods. These studies will be complemented by high-frequency sampling (ten-minute and hourly) during storm and dry-weather conditions to provide insights concerning spatial and temporal variability. Health-risk models (Quantitative Microbial Risk Assessment) will be developed using pathogen and pathogen indicator concentrations as input. The marine toxin work will concern ciguatoxin and beta-N-methylamino-L-alanine (BMAA), both of which were the focus of recent PRCMB studies. Taking advantage of (1) the refinement of an assay (n2a) that is now capable of detecting ciguatoxin in fish tissue at concentrations ten times below the threshold associated with ciguatera symptomology and (2) a collaboration with Hawaiian recreational fishermen, PRCMB scientists will extract and concentrate sufficient ciguatoxin from fish tissue to obtain a molecular structure and will then, in collaboration with scientists at the University of Washington, work toward the development of an antibody-based assay for ciguatoxin. Ciguatoxin research will also involve (1) exploratory refinement of the n2a assay based on generation of nitric oxide by the n2a cell line and (2) an investigation of environmental conditions that trigger ciguatoxin production by taxonomically defined strains of the dinoflagellate Gambierdiscus. The BMAA work will build on initial studies to determine the prevalence of BMAA in marine cyanobacteria and the transfer of this toxin to higher trophic levels. The pharmaceutical studies will take advantage of the more than 2,500 microbial isolates in the PRCMB culture collection that have not yet been screened for bioactivity. Extracts of these cultures will be used in cell-based and molecular assays to determine if they affect the growth of microbial pathogens (Candida albicans, Escherichia coli, Staphlyococcus aureus, multi-drug resistant S. aureus, and vancomycin resistant Enterococcus faecium) or if they exert effects on human adenocarcinma cells, on protein kinase C, or on mitogen-activated protein kinase. Identification of the compounds responsible for reproducible bioactivity in these extracts will be accomplished through bioassay-guided fractionation and spectroscopic analysis (e.g., mass spectrometry, high-field nuclear magnetic resonance spectrometry)The broader impacts of the proposed work fall into several categories. One is certainly the public health endpoints: (i) credible methods that can be used to determine whether coastal waters are safe for recreational use, (ii) a simple, inexpensive assay for ciguatoxin in fish, (iii) a better appreciation of the threat to human health associated with the movement of BMAA through marine food chains, and (iv) the discovery of novel compounds with application to the treatment of human health problems. Second, this is a collaborative proposal with an historically black university (Jackson State University) and a female principal investigator from Stanford. Finally, the PRCMB will continue to train students and to collaborate with other institutions and Ocean and Human Health centers.

这项以成就为基础的太平洋海洋生物医学研究中心（PRCMB）的更新将由夏威夷大学、斯坦福大学和杰克逊州立大学合作进行。研究活动将集中在两个领域：(1)热带海水中的病原体和(2)海洋毒素和药物铅的发现。这项新的研究从逻辑上遵循了PRCMB资助第一阶段取得的成就和发现。病原体和病原体指标工作将重点关注流入海洋的两条河流，一条是热带河流（瓦胡岛的Kaelepulu），另一条是温带河流（加利福尼亚州的圣佩德罗溪）。将使用培养依赖性和非培养依赖性（基于聚合酶链反应）方法，在两条河流进行每月采样，以表征病原体指标和病原体（细菌和病毒）浓度的季节性变化。这些研究将在风暴和干旱天气条件下辅以高频采样（10分钟和每小时），以提供有关空间和时间变化的见解。将利用病原体和病原体指标浓度作为输入，开发健康风险模型（定量微生物风险评估）。海洋毒素工作将涉及雪卡毒素和β - n -甲氨基- l -丙氨酸（BMAA），这两者都是最近PRCMB研究的重点。利用(1)改进的分析（n2a），现在能够检测鱼组织中的雪卡毒素，浓度低于雪卡毒素症状相关阈值的十倍；(2)与夏威夷休闲渔民合作，PRCMB科学家将从鱼组织中提取并浓缩足够的雪卡毒素以获得分子结构，然后将与华盛顿大学的科学家合作，致力于开发一种基于抗体的雪卡毒素检测方法。雪卡毒素的研究还将包括(1)基于n2a细胞系产生一氧化氮的n2a试验的探索性改进和(2)通过分类定义的鞭毛藻冈比亚铁鱼菌株触发雪卡毒素产生的环境条件的调查。BMAA工作将建立在初步研究的基础上，以确定BMAA在海洋蓝藻中的流行程度以及这种毒素向更高营养水平的转移。药物研究将利用PRCMB培养收集中尚未进行生物活性筛选的2500多株微生物分离物。这些培养物的提取物将用于细胞和分子检测，以确定它们是否影响微生物病原体（白色念珠菌、大肠杆菌、金黄色葡萄球菌、耐多药金黄色葡萄球菌和耐万古霉素的粪便肠球菌）的生长，或者它们是否对人腺癌细胞、蛋白激酶C或丝裂原活化蛋白激酶产生影响。对这些提取物中具有可再生生物活性的化合物的鉴定将通过生物测定引导的分馏和光谱分析（例如，质谱，高场核磁共振光谱）来完成。其中之一当然是公共卫生终点：(i)可用于确定沿海水域是否可安全用于娱乐用途的可靠方法；（ii）对鱼类中的雪卡毒素进行简单、廉价的检测；（iii）更好地了解与BMAA通过海洋食物链流动有关的对人类健康的威胁；（iv）发现可应用于治疗人类健康问题的新型化合物。其次，这是一项与历史悠久的黑人大学（杰克逊州立大学）和一位来自斯坦福大学的女首席研究员的合作提案。最后，PRCMB将继续培训学生，并与其他机构以及海洋和人类健康中心合作。